CPT® Code 87380

1. Indications

The CPT® Code 87380 is indicated for the detection of the hepatitis delta agent antigen in patients who are suspected of having a hepatitis D virus infection. The following conditions may warrant the use of this test:

• Hepatitis B Co-infection Patients who are already infected with hepatitis B virus (HBV) and exhibit symptoms of liver disease may require this test to determine the presence of the hepatitis delta agent, which can exacerbate their condition.
• Acute Hepatitis Symptoms Individuals presenting with acute hepatitis symptoms, such as jaundice, fatigue, and abdominal pain, may be tested to identify the cause of their liver inflammation, including the possibility of HDV infection.
• Chronic Hepatitis B Monitoring Patients with chronic hepatitis B may be monitored for the presence of the delta agent, as its detection can indicate a more severe disease progression and the need for more aggressive management.

2. Procedure

The procedure for conducting the test under CPT® Code 87380 involves several key steps to ensure accurate detection of the hepatitis delta agent antigen:

• Step 1: Sample Collection A blood sample is obtained from the patient, typically through venipuncture. This sample is crucial for the subsequent analysis and must be handled with care to maintain its integrity.
• Step 2: Sample Preparation The collected blood sample is either placed in a fixative to preserve the antigen or sent fresh to the laboratory for processing. Proper handling is essential to prevent degradation of the antigen.
• Step 3: Immunoassay Technique Application The laboratory technician employs one of the immunoassay techniques—EIA, ELISA, FIA, or IMCA—to detect the hepatitis delta antigen. Each method involves specific reagents and procedures to bind the antigen to antibodies.
• Step 4: Detection and Measurement After the binding process, a secondary enzyme-labeled antibody is added in EIA and ELISA methods, which produces a color change or fluorescence. In FIA, a fluorescent compound is used, while IMCA utilizes chemiluminescent substances. The resulting reaction is measured to determine the presence and quantity of the antigen.
• Step 5: Result Interpretation The results are assessed qualitatively or semi-quantitatively based on the colorimetric readings or fluorescence emitted, providing critical information regarding the presence of the hepatitis delta agent in the sample.

3. Post-Procedure

After the completion of the test, the laboratory will analyze the results and report them to the requesting physician. It is important for healthcare providers to interpret the results in the context of the patient's clinical history and symptoms. If the hepatitis delta agent is detected, further evaluation and management may be necessary, particularly for patients with existing hepatitis B infection. Follow-up care may include additional testing, monitoring liver function, and discussing treatment options based on the severity of the disease. Patients should be informed about the significance of the results and any necessary lifestyle or medical adjustments that may be required.